A Nanobody‐on‐Quantum Dot Displacement Assay for Rapid and Sensitive Quantification of the Epidermal Growth Factor Receptor (EGFR)
[PHYS]Physics [physics]
EGFRvIII
0301 basic medicine
0303 health sciences
[SDV]Life Sciences [q-bio]
General Chemistry
Single-Domain Antibodies
Catalysis
Communications
[PHYS] Physics [physics]
[SDV] Life Sciences [q-bio]
ErbB Receptors
03 medical and health sciences
Lanthanides
[CHIM] Chemical Sciences
Quantum Dots
FRET
Fluorescence Resonance Energy Transfer
[CHIM]Chemical Sciences
Nanoparticles
Terbium
Diagnostics
DOI:
10.1002/anie.202207797
Publication Date:
2022-06-27T15:29:02Z
AUTHORS (9)
ABSTRACT
Abstract Biosensing approaches that combine small, engineered antibodies (nanobodies) with nanoparticles are often complicated. Here, we show nanobodies different C‐terminal tags can be efficiently attached to a range of the most widely used biocompatible semiconductor quantum dots (QDs). Direct implementation into simplified assay formats was demonstrated by designing rapid and wash‐free mix‐and‐measure immunoassay for epidermal growth factor receptor (EGFR). Terbium complex (Tb)‐labeled hexahistidine‐tagged were specifically displaced from QD surfaces via EGFR‐nanobody binding, leading an EGFR concentration‐dependent decrease Tb‐to‐QD Förster resonance energy transfer (FRET) signal. The detection limit 80±20 pM (16±4 ng mL −1 ) 3‐fold lower than clinical cut‐off concentration soluble up 10‐fold compared conventional sandwich FRET assays required pair nanobodies.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (44)
CITATIONS (10)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....